Rare gene disorder drug may slash heart attack risk
NCT ID NCT06832371
First seen Feb 28, 2026 · Last updated May 17, 2026 · Updated 8 times
Summary
This study looks at whether lomitapide, a medication that lowers extremely high cholesterol, can reduce major heart problems like heart attacks and strokes in people with homozygous familial hypercholesterolemia (HoFH). Researchers will compare heart events in the three years before starting lomitapide to the first three years on the drug. About 73 adults with HoFH from European lipid centers are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette
Torino, Torino, 10126, Italy
-
ARNAS Garibaldi
Catania, Italy, Italy
-
Arcispedale Sant'Anna - Università degli Studi di Ferrara
Ferrara, Emilia-Romagna, 44124, Italy
-
CHRU Lille - Centre Hospitalier Universitaire de Lille
Lille, France
-
CNR Gabriele Monasterio - Centro di Aferesi, Pisa
Pisa, Tuscany, 56124, Italy
-
Centre Hospitalier Universitaire de Lyon (CHU Lyon)
Lyon, France
-
DIMI - Dipartimento di Medicina Interna, Università di Genova
Genova, GE, 16132, Italy
-
Hammersmith Hospital - Imperial College Healthcare NHS Trust
London, England, W12 0HS, United Kingdom
-
Harefield Hospital - Royal Brompton & Harefield NHS Foundation Trust
Harefield, England, United Kingdom
-
Hôpital La Pitié Salpêtrière - Groupe Hospitalier "La Pitié Salpêtrière - Charles Foix"
Paris, France
-
Hôpital de la Conception - Assistance Publique Hôpitaux de Marseille (AP-HM)
Marseille, France
-
METROPOLITAN HOSPITAL, Piraeus
Piraeus, Greece
-
Manchester University Hospital - NHS Foundation Trust
Manchester, England, United Kingdom
-
Ospedale Bassini - ASST Nord Milano
Milan, Lombardy, 20092, Italy
-
Ospedale Borgo Trento - A.O.U. Integrata Verona
Verona, Veneto, 37126, Italy
-
Ospedale Civile di Baggiovara - A.O.U. di Modena
Modena, Emilia-Romagna, 41124, Italy
-
Ospedale San Luigi Gonzaga
Orbassano, Torino, 10043, Italy
-
Ospedale Sant'Anna e San Sebastiano
Caserta, Campania, 81100, Italy
-
Ospedale regionale generale "F. Miulli"
Bari, Italy
-
Policlinico Federico II di Napoli
Naples, Campania, 80131, Italy
-
Policlinico Paolo Giaccone - Università degli Studi di Palermo
Palermo, Sicily, 90127, Italy
-
Policlinico Sant'Orsola - Università di Bologna
Bologna, Emilia-Romagna, 40138, Italy
-
Policlinico Umberto I - Sapienza Università di Roma
Rome, Lazio, 00161, Italy
-
Policlinico di Catanzaro - A.O.U. Mater Domini
Catanzaro, Calabria, 88100, Italy
-
Policlinico di Padova - A.O.U. di Padova
Padova, Veneto, 35128, Italy
-
Queen Elizabeth Hospital Birmingham (QEII - Birmingham)
Birmingham, England, United Kingdom
-
Radboud University Medical Centre
Nijmegen, Netherlands
-
Rotterdam Erasmus Medical Center
Rotterdam, Netherlands
-
Strasbourg University Hospital (CHU Strasbourg)
Strasbourg, France
-
University General Hospital of Ioannina
Ioannina, Greece
Conditions
Explore the condition pages connected to this study.